Author: Nicholas Hall Reports
This essential report examines the key trends in M&A and provides sharp analysis of all the important deals – at a global, regional and local level – since 2010. The acquisition strategies of the leading global marketers are analysed, including development milestones and a look to the future. The report identifies 100 leading M&A targets, each with its own profile, featuring OTC sales 2008-12, top brands and key strengths, along with Nicholas Hall’s expert appraisal.
OTC Market & Trends: A look at the OTC market as a whole, highlighting key trends and analysing the important growth factors region by region.
M&A Trends: Key learnings from past M&A, including the impact of Big Pharma on OTC, M&A as a means of compensating for low organic growth, rationalisation through M&A and growing MNC interest in the emerging markets.
M&A Review of 2010-2013: Detailed analysis of the key deals year by year – on a global, regional and local level – between 2010-13, with a multiples table to help compare amounts paid in selected deals.
M&A Strategy of the Global OTC Top 20: Profiles of leading OTC marketers including J&J, Novartis, Bayer, GSK and Sanofi, featuring the latest sales data from DB6 2013 (top brands, regional & category breakdown), acquisition strategy, development milestones and a look to the future.
Leading M&A Targets: 100 acquisition / j-v targets from around the world profiled, featuring OTC sales 2008-12, leading brands and analysis of notable assets and key benefits.
Future Prospects for the OTC Industry and M&A: Analysis of the outlook for the OTC industry and the future of M&A.
Appendix: M&A Register 2003-2013: Listing all the deals with an OTC impact, back to 200.
Please enter the email address and a message below:
Please enter your details and review your items below
Please send us a message using the form below:
If you wish to receive our promotional material, please tick:
Enter your details below to join our mailing list: